These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20450491)

  • 21. A proposed molecular basis for the selective resveratrol inhibition of the PGHS-1 peroxidase activity.
    Kümmerle AE; Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ; Fraga CA
    Bioorg Med Chem; 2005 Nov; 13(21):5981-5. PubMed ID: 16099662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo.
    El-Achkar GA; Jouni M; Mrad MF; Hirz T; El Hachem N; Khalaf A; Hammoud S; Fayyad-Kazan H; Eid AA; Badran B; Merhi RA; Hachem A; Hamade E; Habib A
    Eur J Pharmacol; 2015 Mar; 750():66-73. PubMed ID: 25617797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of wines and wine constituents on cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase catalytic activity.
    Kutil Z; Temml V; Maghradze D; Pribylova M; Dvorakova M; Schuster D; Vanek T; Landa P
    Mediators Inflamm; 2014; 2014():178931. PubMed ID: 24976682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol.
    Cao D; Wang M; Qiu X; Liu D; Jiang H; Yang N; Xu RM
    Genes Dev; 2015 Jun; 29(12):1316-25. PubMed ID: 26109052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia.
    Candelario-Jalil E; de Oliveira AC; Gräf S; Bhatia HS; Hüll M; Muñoz E; Fiebich BL
    J Neuroinflammation; 2007 Oct; 4():25. PubMed ID: 17927823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1.
    Pacholec M; Bleasdale JE; Chrunyk B; Cunningham D; Flynn D; Garofalo RS; Griffith D; Griffor M; Loulakis P; Pabst B; Qiu X; Stockman B; Thanabal V; Varghese A; Ward J; Withka J; Ahn K
    J Biol Chem; 2010 Mar; 285(11):8340-51. PubMed ID: 20061378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones.
    Abdel-Aziz AA; Abou-Zeid LA; ElTahir KEH; Ayyad RR; El-Sayed MA; El-Azab AS
    Eur J Med Chem; 2016 Oct; 121():410-421. PubMed ID: 27318118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.
    Abdel-Aziz AA; ElTahir KE; Asiri YA
    Eur J Med Chem; 2011 May; 46(5):1648-55. PubMed ID: 21388719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemical and structural diversity in cyclooxygenase protein active sites.
    Huff RG; Bayram E; Tan H; Knutson ST; Knaggs MH; Richon AB; Santago P; Fetrow JS
    Chem Biodivers; 2005 Nov; 2(11):1533-52. PubMed ID: 17191953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells.
    Li Y; Bäckesjö CM; Haldosén LA; Lindgren U
    Eur J Pharmacol; 2009 May; 609(1-3):13-8. PubMed ID: 19285066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
    Milne JC; Lambert PD; Schenk S; Carney DP; Smith JJ; Gagne DJ; Jin L; Boss O; Perni RB; Vu CB; Bemis JE; Xie R; Disch JS; Ng PY; Nunes JJ; Lynch AV; Yang H; Galonek H; Israelian K; Choy W; Iffland A; Lavu S; Medvedik O; Sinclair DA; Olefsky JM; Jirousek MR; Elliott PJ; Westphal CH
    Nature; 2007 Nov; 450(7170):712-6. PubMed ID: 18046409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application.
    Lan F; Weikel KA; Cacicedo JM; Ido Y
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28708087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol.
    Sajish M; Schimmel P
    Nature; 2015 Mar; 519(7543):370-3. PubMed ID: 25533949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol is not a direct activator of SIRT1 enzyme activity.
    Beher D; Wu J; Cumine S; Kim KW; Lu SC; Atangan L; Wang M
    Chem Biol Drug Des; 2009 Dec; 74(6):619-24. PubMed ID: 19843076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.
    Jang M; Cai L; Udeani GO; Slowing KV; Thomas CF; Beecher CW; Fong HH; Farnsworth NR; Kinghorn AD; Mehta RG; Moon RC; Pezzuto JM
    Science; 1997 Jan; 275(5297):218-20. PubMed ID: 8985016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular architecture of the human protein deacetylase Sirt1 and its regulation by AROS and resveratrol.
    Lakshminarasimhan M; Curth U; Moniot S; Mosalaganti S; Raunser S; Steegborn C
    Biosci Rep; 2013 May; 33(3):. PubMed ID: 23548308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A molecular mechanism for direct sirtuin activation by resveratrol.
    Gertz M; Nguyen GT; Fischer F; Suenkel B; Schlicker C; Fränzel B; Tomaschewski J; Aladini F; Becker C; Wolters D; Steegborn C
    PLoS One; 2012; 7(11):e49761. PubMed ID: 23185430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential modulation of cyclooxygenase-mediated prostaglandin production by the putative cancer chemopreventive flavonoids tricin, apigenin and quercetin.
    Al-Fayez M; Cai H; Tunstall R; Steward WP; Gescher AJ
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):816-25. PubMed ID: 16552572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Both cyclooxygenase-1 and cyclooxygenase-2 mediate osteoblast response to titanium surface roughness.
    Boyan BD; Lohmann CH; Sisk M; Liu Y; Sylvia VL; Cochran DL; Dean DD; Schwartz Z
    J Biomed Mater Res; 2001 Jun; 55(3):350-9. PubMed ID: 11255188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential binding mode of diverse cyclooxygenase inhibitors.
    Llorens O; Perez JJ; Palomer A; Mauleon D
    J Mol Graph Model; 2002 Mar; 20(5):359-71. PubMed ID: 11885959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.